Oragenics Receives NYSE American Deficiency Notice for Listing Standards

Oragenics, Inc. was notified by NYSE American LLC on August 26, 2026, for non-compliance with listing standards, specifically Sections 1003(a)(ii) and 1003(a)(iii). The company failed to maintain the required $4 million in stockholders' equity after reporting losses in three of its last four fiscal years. This deficiency raises concerns about its continued listing status, though the company also updated on its Phase IIa clinical trial progress.